A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
droperidol
Class :
Antiemetic agents
Brand Name :
No Data Available.
Synonyms :
droperidol
Class :
Antiemetic agents
Dosage forms & Strengths:
Injectable solution:
2.5 mg/ml
2.5
mg
Solution
Intravenous (IV)
as needed
5
mg
Solution
Intramuscular (IM)
as needed
(Off-label)
5 mg intramuscularly
(Off-label)
5 mg intramuscularly
Dose Modification
In the case of renal or hepatic impairment, use the drug with caution. Safety and efficacy are not seen in these cases
Dosage forms & Strengths
Injectable solution
2.5mg/ml
0.03 - 0.07
mg/kg
Solution
Intravenous (IV)
every 6 hrs
2 - 5
minutes
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effects of CNS depressants
may increase the CNS depressant effect of CNS depressants
acrivastine and pseudoephedrine
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
It may enhance QTc interval when combined with pentamidine
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect CNS Depressants
it increases the toxic or adverse effect of bromopride
it decreases the effect of antipsychotic agents
anticholinergic agents increase the anticholinergic effect of glycopyrrolate
anticholinergic agents decrease the efficacy of levosulpiride
it increases the QTc-prolonging action of QT-prolonging agents
It may enhance QTc interval when combined with perphenazine
It may enhance QTc interval when combined with lithium
QTc interval is increased both by lenvatinib and droperidol
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
it increases the effect of CNS depressants
may increase the QTc interval when combined
may have an increased QTc-prolonging effect when combined with ziprasidone
antipsychotic agents reduce the toxic or adverse effects of amphetamines
anticholinergic agents increase the tachycardiac effect of these products
droperidol decreases the effect of urea cycle disorder agents
droperidol increases the effect of CYP3A4 inhibitors
acetylcholinesterase inhibitors
they decrease the effect of anticholinergic agents
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
It may enhance sedation when combined with a shepherd's purse
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
when ajmaline is used together with droperidol, the risk or seriousness of QTc prolongation is enhanced
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
When droperidol is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When droperidol is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
When droperidol is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
diphenoxylate, when used with droperidol, increases sedation
CNS Depressants may enhance the CNS depressant effect of brexanolone
CNS depressants increase the CNS depressing effect of alcohol
may increase the CNS depressant effect
may increase the CNS depressant effect
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
When droperidol is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
it increases the effect of droperidol by synergism
it decreases the effect of droperidol by antagonism
ethanol and droperidol increase the toxicity of each other
eucalyptus and droperidol, when taken together, increase sedation
sage and droperidol, when taken together, increase sedation
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
Actions and Spectrum:
droperidol is a medication with a variety of actions and a broad spectrum of activity. It is a potent dopamine receptor antagonist and has antiemetic, sedative, and antipsychotic effects.
Antiemetic action: droperidol is often used as an antiemetic agent to prevent or treat nausea and vomiting caused by chemotherapy, surgery, or other causes. It works by blocking dopamine receptors in the chemoreceptor trigger zone in the brain, which helps to prevent nausea and vomiting.
Sedative action: droperidol has sedative properties and is often used in anesthesia and sedation protocols. It works by depressing the central nervous system and producing a calming effect, which can help to reduce anxiety and agitation.
Antipsychotic action: droperidol has antipsychotic properties and is sometimes used to treat psychosis and other psychiatric disorders. It works by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis and agitation.
droperidol has a broad spectrum of activity and is useful in a variety of clinical settings. However, it can also cause side effects such as sedation, respiratory depression, and extrapyramidal symptoms (EPS), which can include involuntary movements of the face, tongue, or limbs. Therefore, it is important to use droperidol with caution and to monitor patients closely for any adverse effects.
Frequency defined
>10%
Restlessness
Anxiety
Extrapyramidal Symptoms
Dystonic reactions
Tardive dyskinesia
Seizure
Sedation
Drowsiness
Swelling of breasts
Weight gain
1-10%
Hallucinations
Akathisia
Orthostatic hypotension
Tachycardia
Nausea
Vomiting
Dysuria
Frequency not defined
Ventricular tachycardia
Black Box Warning:
droperidol carries a black box warning for QT prolongation and torsades de pointes, which is a potentially fatal cardiac arrhythmia. The black box warning indicates that droperidol should be reserved for use in patients who fail to respond to other medications or who are intolerant to other antiemetic agents.
The black box warning also recommends that droperidol be administered only by healthcare professionals who are trained in the administration of general anesthesia and who are familiar with the management of potential complications, such as respiratory depression, hypotension, and cardiac arrhythmias.
In addition, the black box warning advises that patients be closely monitored for signs of QT prolongation and torsades de pointes, including electrocardiogram (ECG) monitoring, and that droperidol should be discontinued immediately if any signs or symptoms of arrhythmias occur.
Contraindication/Caution:
droperidol has several contraindications and precautions that should be considered before administering the medication. These include:
Pregnancy consideration:
No well-controlled studies are reported on pregnant women. droperidol should be used only if potential benefits overweigh the risks
Breastfeeding warnings:
droperidol is not known for its excretion in breastmilk. Lactating females should exercise caution during treatment
Pregnancy category:
Pharmacology:
droperidol is a medication that belongs to a class of drugs known as butyrophenones. It is primarily used as an antipsychotic medication and as an antiemetic (a drug that helps to prevent nausea and vomiting).
The pharmacology of droperidol involves its binding to dopamine receptors in the brain. It acts as a potent dopamine antagonist, meaning that it blocks the effects of dopamine, a neurotransmitter that is involved in reward, motivation, and pleasure.
In addition to its action on dopamine receptors, droperidol also has effects on other receptors in the brain, including serotonin receptors and alpha-adrenergic receptors. These actions contribute to its antiemetic effects.
droperidol is primarily metabolized in the liver and excreted in the urine. Its effects typically last for several hours, and it is administered either by injection or as a transdermal patch.
It is important to note that droperidol can have significant side effects, including sedation, confusion, and a prolonged QT interval (a measure of the electrical activity of the heart). As a result, it is usually reserved for use in situations where other medications have not been effective or are contraindicated.
Pharmacodynamics:
The pharmacodynamics of droperidol involves its action on several different neurotransmitter systems in the brain, including the dopamine, serotonin, and alpha-adrenergic systems.
droperidol acts as a potent antagonist at dopamine receptors in the brain, particularly at D2 receptors. By blocking the effects of dopamine, droperidol can help to reduce symptoms of psychosis and agitation.
In addition to its action on dopamine receptors, droperidol also has effects on serotonin receptors in the brain, particularly 5-HT2A receptors. This contributes to its antiemetic effects by reducing the activity of the chemoreceptor trigger zone in the brainstem, which is responsible for the sensation of nausea and vomiting.
droperidol also has effects on alpha-adrenergic receptors in the brain, which can contribute to its sedative effects.
The pharmacodynamics of droperidol can vary depending on the dose and the individual’s response to the medication. Higher doses of droperidol can lead to greater dopamine receptor blockade and more potent sedative effects, while lower doses may be sufficient to achieve antiemetic effects.
Administration:
droperidol is typically administered by injection, either intravenously (IV) or intramuscularly (IM). The dose and frequency of administration will depend on the specific indication for which the medication is being used, as well as the patient’s individual characteristics (such as age, weight, and medical history).
For the treatment of psychosis or agitation, a typical starting dose of droperidol may be around 2.5-5 mg given IM or IV. This dose can be repeated as needed, with a maximum recommended daily dose of 20 mg.
For the prevention or treatment of nausea and vomiting, a typical dose of droperidol may be around 0.625-1.25 mg given IV or IM, with a maximum recommended daily dose of 2.5 mg.
It is important to note that droperidol can have significant side effects, particularly at higher doses, and its use requires close monitoring of the patient’s cardiovascular function. In some cases, electrocardiogram (ECG) monitoring may be necessary, particularly in patients with a history of cardiac arrhythmias or other cardiac risk factors.
Patient information leaflet
Generic Name: droperidol
Pronounced: dro-PER-i-dol
Why do we use droperidol?
droperidol is primarily used for two main indications: the treatment of psychosis and agitation, and the prevention or treatment of nausea and vomiting.
In the treatment of psychosis and agitation, droperidol is used as an antipsychotic medication to help control symptoms such as hallucinations, delusions, and aggressive behavior. It works by blocking the effects of dopamine in the brain, which is believed to be involved in the development of these symptoms.
In the prevention or treatment of nausea and vomiting, droperidol is used as an antiemetic medication to help reduce the sensation of nausea and prevent vomiting. It works by blocking serotonin receptors in the brain, which are involved in the regulation of nausea and vomiting.
droperidol may also be used in certain surgical or diagnostic procedures to help manage agitation or prevent nausea and vomiting related to the procedure.
It is important to note that droperidol can have significant side effects, particularly at higher doses, and its use requires close monitoring of the patient’s cardiovascular function. As a result, its use is typically reserved for situations where other medications have not been effective or are contraindicated.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
